alexa Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report | OMICS International| Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Cancer Sci Ther/Vol.10.6 149(2018),
  • DOI: 10.4172/1948-5956.1000534

Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report

Cinzia Pellegrini1, Beatrice Casadei1, Claudia Cellini2, Lisa Argnani1, Michele Cavo1 and Pier Luigi Zinzani1*
1Institute of Hematology “L. e. A. Seràgnoli”, University of Bologna, Bologna, Italy
2Unit of Hematology, Santa Maria Delle Croci Hospital, , Ravenna, Italy
*Corresponding Author : Pier Luigi Zinzani, Institute of Hematology “L. e. A. Seràgnoli”, University of Bologna, Bologna, Italy, Tel: +390512143680, Fax: +390512144037, Email: [email protected]

Received Date: May 25, 2018 / Accepted Date: Jun 18, 2018 / Published Date: Jun 20, 2018

Abstract

Background: Nivolumab and pembrolizumab are the first two US FDA-approved monoclonal antibodies targeting PD-1 for Hodgkin lymphoma (HL) and provide promising results in the relapsed/refractory setting (HL patients relapsing after autologous stem cell transplantation [ASCT], or with chemorefractory disease and/ or ineligible for ASCT). An interesting area of ongoing research is the possibility of combining different immune checkpoint inhibitors given concomitantly or sequentially in the attempt to maximize the patient responsiveness. Case report: A heavily pre-treated young woman affected by HL, after several attempts, obtained a complete response after ASCT thanks to the bridge with pembrolizumab. After relapse, the patient achieved again a complete response with nivolumab, bridging her to allotransplant. The patient is still in response to a year since the transplant. Discussion and Conclusion: This is the first report which witnesses the safety and the antitumor activity of interchangeable anti-PD1 monoclonal antibodies administered as a retreatment option and as a bridge to allotransplant in a patient who previously got an objective response to another anti-PD1 which brought her to autologous transplant. Retreatment with anti-PD1 monoclonal antibodies could be considered in therapeutic algorithm of relapsed/refractory HL.

Keywords: Hodgkin lymphoma; Anti-PD1 monoclonal antibodies; Autologous stem cell transplant; Allogeneic transplantation; Retreatment

Citation: Pellegrini C, Casadei B, Cellini C, Argnani L, Cavo M, et al. (2018) Sequential Double Bridging to Transplant with Diversified Anti-PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report. J Cancer Sci Ther 10: 149-151. Doi: 10.4172/1948-5956.1000534

Copyright: © 2018 Pellegrini C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
Article Usage
  • Total views: 1959
  • [From(publication date): 0-2018 - Dec 15, 2019]
  • Breakdown by view type
  • HTML page views: 1905
  • PDF downloads: 54
Top